Roche wins the race for Intermune
Enlarge image


Roche wins the race for Intermune

24.08.2014 - Roche has closed the deal on Intermune – the Swiss drugmaker has fully acquired the US biotech for US$8.3bn.

Some of Europe’s biggest pharma companies such as British Glaxosmithkline and French Sanofi were competing for Intermune, insiders reported last week. Now, Roche has won the bidding war and will acquire the biotechnology company at a price of US$74 per share in an all-cash transaction – a premium of 38 percent on the company’s closing price on 22 August and a premium of 63 percent on its unaffected closing price on 12 August.

California-based Intermune is focused on the research, development and commercialisation of therapies in pulmonology and fibrotic diseases. With its lead medicine pirfenidone, the company has a pulmonary fibrosis treatment already on the market in the EU and Canada and under regulatory review in the United States and Roche now plans to launch the drug in the US this year. Orally active, anti-fibrotic agent Pirfenidone inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions, including proliferation and differentiation, and plays a key role in fibrosis. The drug – marketed in the EU as Esbriet – will allow Roche to broaden its respiratory portfolio, which currently contains the lung disease products Pulmozyme and Xolair, both on the US market. Roche plans a smooth transition of Intermune employees and operations into the Roche organisation.

Under the terms of the merger agreement, Roche will commence a tender offer no later than 29 August 2014, to acquire all outstanding shares of Intermune common stock, and Intermune will file a recommendation statement containing the unanimous recommendation of its  board that Intermune’s shareholders tender their shares to Roche. The transaction is expected to be neutral to core earnings per share in 2015 and accretive from 2016 onwards. The merger agreement has been approved by the boards of Intermune and Roche.



24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.


20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.


15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.


13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.


11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.


08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.


06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.


03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

© 2007-2014 BIOCOM


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%


  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%


  • SANTHERA83.50 CHF27.5%
  • BB BIOTECH140.45 EUR6.3%
  • HBM86.00 CHF3.7%


  • MOLOGEN7.85 EUR-17.4%
  • WILEX2.36 EUR-15.7%
  • MEDIGENE4.48 EUR-12.5%


  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR185.1%


  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-67.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 27.08.2014